PROSPECTIVE BIOLOGICAL ACTIVE COMPOUNDS AMONG 7-SUBSTITUTED OF 3-BENZYL-8-PROPYLXANTHINES FOR TREATMENT OF METABOLIC SYNDROME PATHOLOGIES
Aim – the search for biologically active compounds with diuretic and hypoglycemic action among 7-substituted of 3-benzyl-8-propylxanthines, which can be used for the treatment of pathologies of “metabolic syndrome”.
Materials and methods. 30 new chemical compounds among derivatives of 7-substituted of 3-benzyl-8-propylxanthines by PASS prediction filter were chosen for diuretic and hypoglycemic activity researches. Diuretic, hypoglycemic activity and for the most active compounds – the acute toxicity were studied in vivo. The molecular docking, which is based on EADock DSS mechanism of the modulation displayed the interaction between some of functional groups inside discovered xanthine ligands and known receptors and enzymes presented in Ligand-protein Database of Swiss Institute of Bioinformatics.
Results. It has been shown that synthesized compounds displayed strong diuretic and medium hypoglycemic activities. The molecular docking modulation (SwissDock) of interaction of xanthine derivatives hits with proposed receptors and enzymes revealed prospective of using 7-substituted of 3-benzyl-8-propylxanthines as potential drugs for treatment of metabolic syndrome pathologies.
Conclusion. The diuretic activity of the new 23 compounds of 7-substituted of 3-benzyl-8-propylxanthines and hypoglycemic activity of the new 7 derivatives of 7-substituted of 3-benzyl-8-propylxanthines was studied. Results of performed investigation illustrate that 7-substituted of 3-benzyl-8-propylxanthines demonstrate biological activity comparable to standard drugs. We also proposed probable molecular targets for the most active compounds by molecular docking method. It was shown that derivatives of 7-substituted of 3-benzyl-8-propylxanthines can be used for metabolic syndrome disorders prevention.
Gharipour, M., Sadeghi, M., Hosseini, M., Andalib, E., Boroujeni, M. B., Sarrafzadegan, N. (2015) Effect of age on the phenotype of metabolic syndrome in developing country. Adv Biomed Res., 4, 103.
Grundy, S. M. (2016). Overnutrition, ectopic lipid and the metabolic syndrome. Journal of Investigative Medicine, 64 (6), 1082–1086. doi: http://doi.org/10.1136/jim-2016-000155
Saklayen, M. G. (2018). The Global Epidemic of the Metabolic Syndrome. Current Hypertension Reports, 20 (2). doi: http://doi.org/10.1007/s11906-018-0812-z
National Diabetes Statistics Report (2017). Available at: http://dev.diabetes.org/sites/default/files/2019-06/cdc-statistics-report-2017.pdf
Clearfield, M., Pearce, M., Nibbe, Y., Crotty, D., Wagner, A. (2013). The “New Deadly Quartet” for Cardiovascular Disease in the 21st Century: Obesity, Metabolic Syndrome, Inflammation and Climate Change: How Does Statin Therapy Fit into this Equation? Current Atherosclerosis Reports, 16 (1). doi: http://doi.org/10.1007/s11883-013-0380-2
Vitaku, E., Smith, D. T., Njardarson, J. T. (2014). Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals. Journal of Medicinal Chemistry, 57 (24), 10257–10274. doi: http://doi.org/10.1021/jm501100b
Levich, S., Aleksandrova, K., Belenichev, I., Shkoda, A. (2013). Cerebroprotective activity of 3-benzylxanthine derivative – compound Ale-15, in conditions of bilateral common carotid arteries ligation (ischemic stroke). International Journal of Basic & Clinical Pharmacology, 2 (6), 705–710. doi: http://doi.org/10.5455/2319-2003.ijbcp20131207
Aleksandrova, K. V., Belenichev, I. F., Shkoda, O. S. (2016). Influence of 3-methylxanthine derivative on the morphological and functional characteristics of neurons of sensorimotor cortex of rats with experimental intracerebral hemorrhage. Journal of cerebral blood flow and metabolism, 36, 787.
Mikhal’chenko, E. K., Аleksandrova, K. V., Levich, S. V., Korzhova, A. S. (2017). Synthesis and physical-chemical properties of functional derivatives of 3-benzyl-8-propylxanthinyl-7-acetic acid. Current Issues in Pharmacy and Medicine: Science and Practice, 10 (2), 141–146. doi: http://doi.org/10.14739/2409-2932.2017.2.103521
Aleksandrova, K. V., Mykhalchenko, Ye. K., Pruhlo, Ye. S., Sinchenko, D. M. (2018). Pat. No. 128510 UA. Hidrazyd 3-benzyl-8-propilksantyn-7-il atsetatnoi kysloty, yakyi vyiavliaie diuretychnu diiu. MPK: S07D 473/00. No u201802221 declareted: 05.03.2018; published: 25.09.2018, Bul. No. 18
Directive 2010/63/EU of the European Parliament and of the Council. (2016). Official Journal of the European Union.
Berkhin, Ye. B. (1977). Metody izucheniya deistviya novykh khimicheskikh soyedineniy na funkciyu pochek. Khimiko-farmatsevtychnyi zhurnal, 11 (5), 3–11.
Devi, K., Khanam, S., Rabbani, S. (2010). Protective role of glibenclamide against nicotinamide-streptozotocin induced nuclear damage in diabetic Wistar rats. Journal of Pharmacology and Pharmacotherapeutics, 1 (1), 18–23. doi: http://doi.org/10.4103/0976-500x.64531
Grosdidier, A., Zoete, V., Michielin, O. (2011). SwissDock, a protein-small molecule docking web service based on EADock DSS. Nucleic Acids Research, 39, 270–277. doi: http://doi.org/10.1093/nar/gkr366
Grosdidier, A., Zoete, V., Michielin, O. (2011). Fast docking using the CHARMM force field with EADock DSS. Journal of Computational Chemistry, 32 (10), 2149–2159. doi: http://doi.org/10.1002/jcc.21797
Klei, H. E. (2013). Crystal structure of dipeptidyl-peptidase 4 (CD26, adenosine deaminase complexing protein 2) (DPP-IV-WT) complex with bms-767778 AKA 2-(3-(aminomethyl)-4-(2,4- dichlorophenyl)-2-methyl-5-oxo-5,7-dihydro-6h-pyrrolo[3,4- b]pyridin-6-yl)-n,n-dimethylacetamide. doi: http://doi.org/10.2210/pdb4jh0/pdb
Loenze, P., Schimanski-Breves, S., Engel, C. K. (2012). Crystal Structure of 11beta-Hydroxysteroid Dehydrogenase 1 (11b-HSD1) in Complex with Urea Inhibitor. doi: http://doi.org/10.2210/pdb3qqp/pdb
Mueller, J. J., Schupp, M., Unger, T., Kintscher, U., Heinemann, U. (2011). Ligand binding domain of human ppar-gamma in complex with the agonist pioglitazone. doi: http://doi.org/10.2210/pdb2xkw/pdb
Cheng, R. K. Y., Segala, E., Robertson, N., Deflorian, F., Dore, A. S., Errey, J. C. et. al. (2017). Crystal structure of stabilized A1 receptor in complex with PSB36 at 3.3A resolution. doi: http://doi.org/10.2210/pdb5n2s/pdb
Kameoka, J., Tanaka, T., Nojima, Y., Schlossman, S., Morimoto, C. (1993). Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science, 261 (5120), 466–469. doi: http://doi.org/10.1126/science.8101391
Marathe, C. S., Rayner, C. K., Jones, K. L., Horowitz, M. (2013). Glucagon-like peptides 1 and 2 in health and disease: A review. Peptides, 44, 75–86. doi: http://doi.org/10.1016/j.peptides.2013.01.014
Meier, J. J., Nauck, M. A. (2005). Glucagon-like peptide 1(GLP-1) in biology and pathology. Diabetes/Metabolism Research and Reviews, 21 (2), 91–117. doi: http://doi.org/10.1002/dmrr.538
Hoehn, K., Marieb, E. N. (2010). Human Anatomy & Physiology. San Francisco: Benjamin Cummings.
Michalik, L., Auwerx, J., Berger, J. P., Chatterjee, V. K., Glass, C. K., Gonzalez, F. J. et. al. (2006). International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors. Pharmacological Reviews, 58 (4), 726–741. doi: http://doi.org/10.1124/pr.58.4.5
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. (2002). Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA: The Journal of the American Medical Association, 288 (23), 2981–2997. doi: http://doi.org/10.1001/jama.288.23.2981
Singh, N., Shreshtha, A. K., Thakur, M. S., Patra, S. (2018). Xanthine scaffold: scope and potential in drug development. Heliyon, 4 (10), e00829. doi: http://doi.org/10.1016/j.heliyon.2018.e00829
Copyright (c) 2019 Ð•Ð²Ð³ÐµÐ½Ð¸Ð¹ ÐšÐ¾Ð½ÑÑ‚Ð°Ð½Ñ‚Ð¸Ð½Ð¾Ð²Ð¸Ñ‡ ÐœÐ¸Ñ…Ð°Ð»ÑŒÑ‡ÐµÐ½ÐºÐ¾
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.